+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction



Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction



European Heart Journal 25(20): 1822-1828



Peri-procedural non-Q-wave myocardial infarction is a frequent and prognostically important complication of percutaneous coronary intervention (PCI). It has been postulated that statins may reduce the rate of myocardial injury after PCI. Four hundred and fifty-one patients scheduled for elective PCI and not on statins were randomly assigned to either no treatment or to statin treatment. Statin administration was started at least 3 days before the procedure.Incidence of peri-procedural myocardial injury was assessed by analysis of creatinine kinase myocardial isoenzyme (CK-MB: upper limit of normal [ULN] 3.5 ng/ml) and cardiac troponin I (cTn I, ULN 0.10 ng/ml) before, 6 and 12 h after the intervention. A large non-Q-wave myocardial infarction was defined as a CK-MB elevation >5 times ULN alone or associated with chest pain or ST segment or T wave abnormalities. Median CK-MB peak after PCI was 1.70 (interquartile ranges 1.10-3.70) ng/ml in the Statin group and 2.20 (1.30-5.60) ng/ml in the Control group (p=0.015). Median peak of cTnI after PCI was 0.13 (0.05-0.45) ng/ml in the Statin group and 0.21 (0.06-0.85) ng/ml in the Control group (p=0.033). The incidence of a large non-Q-wave myocardial infarction was 8.0% in the Statin group and 15.6% in the Control group (p=0.012: OR=0.47; 95% CI=0.26-0.86). The incidence of cTnI elevation >5 times ULN was 23.5% in the Statin group and 32% in the Control group (p=0.043: OR=0.65; 95% CI=0.42-0.98). By logistic regression analysis, the independent predictors of CK-MB elevation >5 times ULN after PCI were intra-procedural angiographic complications (OR=9.36; 95% CI=3.06-28.64; p<0.001), statin pre-treatment (OR=0.33; 95% CI=0.13-0.86; p=0.023) and age >65 years (OR=2.58; 95% CI=1.09-6.11; p=0.031). Pre-procedural statin therapy reduces the incidence of large non-Q-wave myocardial infarction after PCI.

(PDF emailed within 0-6 h: $19.90)

Accession: 012581477

Download citation: RISBibTeXText

PMID: 15474697

DOI: 10.1016/j.ehj.2004.07.017


Related references

Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Acc Current Journal Review 14(2): 45-0, 2005

Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiology in Review 20(6): 319-324, 2013

High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events. Evidence-Based Medicine 17(1): 13-14, 2011

High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 3-day major cardiac adverse events. Evidence-Based Medicine 17(1): 13-14, 2012

Impact on prognosis of periprocedural myocardial infarction after percutaneous coronary intervention. Journal of Interventional Cardiology 27(5): 482-490, 2016

Impact of coronary plaque burden and composition on periprocedural myocardial infarction and coronary flow reserve after percutaneous coronary intervention. International Heart Journal 55(5): 391-396, 2014

Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study. International Journal of Cardiology 168(3): 2494-2497, 2014

Effect of High-Dose Statin Pretreatment on the Incidence of Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: Grading the Evidence Through a Cumulative Meta-analysis. Clinical Cardiology 38(11): 668-678, 2016

Impact of statin usage patterns on outcomes after percutaneous coronary intervention in acute myocardial infarction: Korea Working Group on Myocardial Infarction registry (KorMI) study. Journal of Geriatric Cardiology 11(2): 93-99, 2014

Impact of crossing technique on the incidence of periprocedural myocardial infarction during chronic total occlusion percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 88(1): 1-6, 2017

High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials. Plos One 9(12): E113352, 2015

TCT-671 Clinical impact of periprocedural myocardial infarction according to various definitions in patients underwent percutaneous coronary intervention with drug eluting stent. Journal of the American College of Cardiology 70(18): B293-B294, 2017

Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. American Journal of Cardiology 94(11): 1363-1366, 2004

Impact of statins preloading before PCI on periprocedural myocardial infarction among stable angina pectoris patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine 2018, 2018

Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention. American Journal of Cardiology 110(10): 1397-1404, 2013